Surmodics Stock Price, News & Analysis (NASDAQ:SRDX)

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SRDX shares.
View SRDX analyst ratings or view top-rated stocks.

2 brokers have issued 1 year price targets for Surmodics' stock. Their SRDX share price targets range from $44.00 to $71.00. On average, they expect the company's share price to reach $57.50 in the next year. This suggests a possible upside of 70.9% from the stock's current price.
View analysts price targets for SRDX or view top-rated stocks among Wall Street analysts.

Surmodics' stock was trading at $34.12 on January 1st, 2023. Since then, SRDX stock has decreased by 1.4% and is now trading at $33.64.
View the best growth stocks for 2023 here.

Surmodics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 235,300 shares, an increase of 71.0% from the October 31st total of 137,600 shares. Based on an average trading volume of 63,100 shares, the days-to-cover ratio is currently 3.7 days. Approximately 1.7% of the shares of the stock are short sold.
View Surmodics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 5th 2024.
View our SRDX earnings forecast.

Surmodics, Inc. (NASDAQ:SRDX) released its earnings results on Wednesday, November, 8th. The company reported $0.53 EPS for the quarter, topping analysts' consensus estimates of $0.16 by $0.37. The company had revenue of $27.97 million for the quarter, compared to analyst estimates of $26 million. Surmodics had a negative net margin of 1.16% and a positive trailing twelve-month return on equity of 1.99%.

Invesco Nasdaq Future Gen 200 ETF holds 1,909 shares of SRDX stock, representing 0.85% of its portfolio.

Surmodics issued an update on its FY 2024 earnings guidance on Wednesday, November, 8th. The company provided earnings per share guidance of -$1.32--$0.97 for the period, compared to the consensus estimate of -$0.20. The company issued revenue guidance of $112.00 million-$117.00 million, compared to the consensus revenue estimate of $130.88 million.

8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX).

Surmodics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (2.51%), Kennedy Capital Management LLC (1.63%), Jacobs Levy Equity Management Inc. (0.99%), Northern Trust Corp (0.97%), Salem Investment Counselors Inc. (0.91%) and Charles Schwab Investment Management Inc. (0.78%). Insiders that own company stock include Charles W Olson, Charles W Olson, David Dantzker, Gary R Maharaj, John D Manders, Jose H Bedoya, Jose H Bedoya, Joseph J Stich, Joseph J Stich and Ronald B Sr Kalich Sr.
View institutional ownership trends.

Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.